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stem cells into endothelial cells. The stem cells were derived from
bone marrow by CD34 selection, and were stimulated with either
m-CSF or PTN alone or a combination of m-CSF and PTN or no
treatment for 7 days. Real-time PCR analysis showed that the
m-CSF and PTN combination markedly increased endothelial cell
marker expression and decreased monocyte marker (CD68 and
c-fms) expression in this stem cell population. When induced with
PTN alone, the stem cells exhibited slightly increasing expression
of endothelial markers. These experiments deﬁne a previously
unrecognized novel mechanism leading to angiogenesis in cancer
patients: the transdifferentiation of monocytes into endothelial
cells by a factor highly produced by tumor cells. They also suggest
a potential new speciﬁc target to inhibit angiogenesis—pleiotro-
phin—which may have profound clinical implications.
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BONE MARROW STEM CELL TRANSPLANTATION IN NEURODEGENERA-
TIVE AND CEREBROVASCULAR DISEASE: PRELIMINARY REPORT
Ozbabalik, D.B., Gulbas, Z., Adapinar, B., Ak, I., Gulel, B. Osmangazi
University Medical Faculty, Eskisehir, Turkey.
Stem cells with self-renewal and multilineage potential are con-
sidered good candidates for cell replacement of damaged nervous
tissue in cerebrovascular and neurodegenerative disease. Most of
the knowledge about the role of stem cells in the progression of
these diseases have been based on experimental evidence. Until
now, there has been no human study showing the effectiveness of
stem cell transplantation in neurologic disease. In this study we
attempted to test whether bone marrow stem cells can improve the
functional, radiologic, and metabolic outcomes in patients with
vascular dementia and ischemic stroke with intra-arterial injection.
Seven patients, (3 female and 4 male; mean age  SD, 68.23 
11.2 years) were included in the study. Patients were selected from
among chronic poststroke and/or vascular dementia patients who
did not respond to classical therapy. Barthel, NIH, and MMSE
scales were used to record mental and motor status, and MR and
SPECT were used to record radiologic and metabolic status before
and 30, 60 and 120 days after the procedure. After the patients were
given neurologic examinations, their bone marrow was aspirated,
cultured in Teﬂon bags, and proliferated during 24 hours. Cul-
tured bone marrow was given to patients intra-arterially and an-
giographically under sterile conditions.
Functionally and mentally, all patients showed improvement in
Barthel, NIH, and MMSE scales 60 days after the procedure, but
the differences were not statistically signiﬁcant (ﬁrst Barthel,
9.85 2.67, last Barthel, 11.28 2.69, [P .32]; ﬁrst NIH, 9.00
2.63, last NIH, 7.42  2.19 [P  .16]; ﬁrst MMSE, 10.71  3.73,
last MMSE, 17.00 4.69 [P  .63]).
In terms of radiology, volumetric improvement on MR was seen
after the procedure (Cavalier volumetric method; P  .047). On
SPECT, cerebral metabolism was observed to increase in 3 patients
quantatively. Finally, we observed a trend of clinical improvement in
our patients. But our study has some limitations, such as a small
number of patients. Nonetheless, in light of our ﬁrst results, we can
say that otology bone marrow stem cell transplantation may provide
new hope in the treatment of neurodegenerative disease.
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BIOLUMINESCENT TRACKING OF CANDIDATE LEUKEMIC STEM CELL
ENGRAFTMENT IN IMMUNOCOMPROMISED MICE
Jamieson, C.H.M., Karimi, M., Creusot, R., Fathman, C.G.,
Negrin, R., Weissman, I.L. Stanford University School of Medicine,
Stanford, CA.
Background: We investigated whether leukemic stem cells
(LSCs) involved in CML progression use the beta-catenin pathway
for self-renewal and also whether inhibition of beta-catenin with
axin prevents engraftment of leukemic stem cells in an immuno-
compromised mouse model using bioluminescent tracking. Meth-
ods: We used ﬂuorescence-activated cell sorting (FACS) to isolate
hematopoietic stem cells (HSCs), common myeloid progenitors
(CMPs), granulocyte/macrophage progenitors (GMPs), and
megakaryocyte/erythroid progenitors (MEPs) from normal mar-
row, cord blood, or advanced-phase CML. In vitro replating assays
were used to identify self-renewing cells as candidate leukemic
stem cells, and the dependence of self-renewal on beta-catenin
activation was tested by lentiviral transduction of hematopoietic
progenitors with axin, an inhibitor of the beta-catenin pathway.
CML HSCs, CMPs, GMPs, or CD3438 cells were transduced
with a lentiviral luciferase GFP vector with or without axin, trans-
planted intrahepatically into newborn T-, B-, and NK-deﬁcient
mice and monitored for engraftment via weekly bioluminescent
imaging as well as tail bleeding to detect GFP-positive cells. Re-
sults: When compared with normal marrow, the GMP pool from
patients in blast crisis and imatinib-resistant CML was expanded
and had elevated levels of nuclear beta-catenin. Unlike normal
GMPs, CML GMPs formed self-renewing replatable myeloid col-
onies, and in vitro self-renewal capacity was reduced by enforced
expression of axin. Although CML HSC showed evidence of early
engraftment, committed progenitors, such as GMP, expanded
more readily in vivo. and their growth was inhibited by pretreat-
ment with axin. Conclusions: Activation of beta-catenin in CML
granulocyte/macrophage progenitors likely enhances their self-
renewal and leukemic activity. Speciﬁc beta-catenin inhibitors such
as axin block this aberrant self-renewal activity in vitro and in vivo.
Finally, the use of bioluminescent imaging of leukemic/cancer
stem cell engraftment in vivo using a newborn immunocompro-
mised mouse model provides a robust tool for assessing response of
cancer stem cells to molecularly targeted therapy.
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EFFECTS AND KINETICS OF ANTI–C-KIT MONOCONAL ANTIBODY
ACK-2 ON HEMATOPOIESIS AND HEMATOPOIETIC PROGENITORS AND
ITS ABILITY TO CONDITION FOR BONE MARROW TRANSPLANTATION
Kraft, D.L., Weissman, I.L. Stanford University School of Medicine,
Stanford University, CA.
Background: The stem cell receptor factor receptor c-Kit is ex-
pressed on hematopoeitic stem cell (HSC) and progenitor cell popu-
lations. ACK-2 is an anti-mouse c-kit mAb that has been shown to
antagonize the function of c-kit and deplete the bone marrow of
treated mice. We wished to characterize the effect and kinetics of
ACK-2 on the peripheral blood cell counts and marrow HSC and
progenitor populations. We also tested the hypothesis that treatment
with ACK-2 may serve as a novel means of nonmyeloablative condi-
tioning for HSC transplantation.Methods: Adult C57/BLmice were
injected either intravenously or intraperitonealy (IP) with 1 mg of
ACK2 mAb on days 0, 2, and 4. Peripheral blood cell counts, includ-
ing WBC differentials, were followed over time in recipient mice.
Peripheral blood and bonemarrow was analyzed at day 7, andmarrow
was analyzed for fraction and proportions of HSC, common myeloid
progenitors (CMPs), granulocyte macrophage progenitors (GMPs),
and macrophage erythrocyte progenitors (MEPs). A subset of Ly5.1
mice that had received ACK2mAb on days 0, 2, and 4 received a bone
marrow transplantation on day 7 with 1106 bone marrow cells from
a congenic Ly5.2 donor. Results: Both IV and IP administration of
ACK-2 resulted in rapid development of anemia, neutropenia, and
thrombocytopenia (see the table for results). Analysis of peripheral
blood revealed a decrease in Mac-1 cells from 12.2% of circulating
WBCs in untreated controls to 3.1% at day 7, whereas the proportion
of B220 B cells increased frommean of 49.7% in controls to 72.7%.
The fraction of circulating T cells decreased from 24.5% to 11.1% at
day 7. The bone marrow fraction of KTLS HSC decreased from
0.07% of total marrow cells in controls to 0.003% in ACK-2–treated
mice. The marrow fractions of CMP and GMP all decreased in
treatedmice, with a proportional drop in CMP progenitors from 12%
in untreated mice to 4.7% in treated mice. ACK-2–treated mice
transplanted with Ly5.2 congenic marrow and analyzed at D21
showed no evidence of donor-derived cells in the peripheral blood,
compared with 83% Ly5.2 donor-derived cells in control mice re-
ceiving 9 Gy of radiation. Coclusions: The anti–c-kit mAb ACK-2
rapidly induces anemia, neutropenia, and thrombocytopenia with cor-
relating decreases in the numbers of marrow HSC and other progen-
itor populations. Despite the ablative action of the ACK-2 on marrow
populations, it does not appear to enable engraftment of syngeneic
bone marrow.
Poster Session II
86
